Clinical pharmacokinetics of bevacizumab in patients with solid tumors. - Wikidata - awgldk - TriplyDB

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

http://www.wikidata.org/entity/Q51718897

about

Aflibercept Population pharmacokinetics of bevacizumab in cancer patients with external validation Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing.Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study.A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Tri [Current therapeutic options in retinopathy of prematurity].Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future.Changes in protein level in the cerebrospinal fluid of a patient with cerebral radiation necrosis treated with bevacizumab.Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab Computational modeling of tumor response to vascular-targeting therapies--part I: validation Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma.Monitoring monoclonal antibody delivery in oncology: the example of bevacizumab A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer Bevacizumab.Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects.Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data.Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation.Efficacy and safety of bevacizumab for the treatment of glioblastoma.Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature.Bevacizumab for the treatment of glioblastoma.Biomarkers in advanced colorectal cancer: challenges in translating clinical research into practice Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience

P2860

Q24600199-6B319465-5072-48D0-9644-674341D33EE9 Q26779580-6D9A00D7-ED19-40A1-8A65-445D48CAC583 Q28257098-F7AF3BE1-CABE-4912-9DA3-15D9F14BD019 Q30564565-FD4B9FBD-0DA7-4AF4-BAF8-87E0A3F50CB8 Q30831967-39E132CB-DC80-44C9-8ED1-3253F3DC73EA Q33413979-0CD1A9DC-6FF4-4B66-AC5D-487ADDCE454D Q33597441-1134FDA8-F13D-4E3D-88E9-1D1979BC17DF Q33624977-F372C0E6-E33E-4D1D-A043-3B8A9E8CCD46 Q33708140-9D357479-DB45-48A4-B315-AEE40C13EED8 Q33813626-BDBACF8A-91E9-4B75-8AEE-81838CAD3D3E Q33831958-C5E63039-9E4F-4B0E-9293-8DB4D436F1F4 Q34308997-4ACA5789-29F7-40A8-9257-417D87FFB36E Q34403375-86C1041C-E7FC-4EA6-8548-3757F3789BB8 Q34448438-D43335BE-669C-4433-B3C0-BBA57AA097D9 Q34501395-39473CFF-CBC7-4F7F-B3D0-4A90D2DBB41E Q34554380-06D4AFB0-BC71-40D7-AAC1-E643C5A17987 Q34680316-2C93730A-EBC1-4DC4-8E01-8B990B94383A Q34694813-501F805E-66AD-49AF-9D03-E7764DE99F22 Q34725648-728813D8-2224-4F36-9E41-A64EC560E5A2 Q34943946-DEBB5155-96D2-4FEF-8DC8-3BA367D12A4D Q34951074-1FC34FEA-7685-4657-B496-5D7B033DDDA6 Q35129364-435C5CC4-4295-4C6C-9B6D-A291022267D8 Q35193385-3B78F33C-9B1E-4106-A9BA-0DA6BE9554E3 Q35226694-63E97F57-64FA-4B1D-9533-2819A2882D72 Q35584072-73F851C8-D6FC-4888-B62E-C02D24ADA85F Q35584234-9A18CCC7-9FCC-4849-B731-8CA6631EE424 Q35914787-89A52213-1025-4F7A-BFCD-FB391E155427 Q35918874-B3D66829-77F6-4422-811C-3A031575B612 Q35966871-AEA12647-AC96-4323-837A-C96A65164127 Q36213618-FA7C43B4-589D-49A3-8E32-663F45DC1855 Q36361160-3B0F1D54-7CCE-47E9-BF0F-8B07254A68BF Q36410210-2F83CA10-CFFA-4AED-8983-0031A85269F5 Q36523864-486369E3-9BD9-49F1-A3C7-F3329081F002 Q36806646-118837C7-E7D1-4D11-97E9-2262C99E0BE3 Q36915007-49D730F8-7801-4A9A-B82C-6A86C0E800AF Q36929502-3FA004C6-7371-4366-B81E-89D345CDDBCE Q37132680-D3028C2E-6D4C-4C59-BDE4-A4869814F703 Q37298794-858E64E7-D155-4B82-9F5E-6B480FB92EFE Q37345045-0AD98BAD-A498-4404-9ECD-564444F9A8C0 Q37372172-5808350B-CDBA-430B-B0D3-8D1971AA811B

P2860

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

http://www.wikidata.org/entity/Q51718897

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

@en

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

@nl

type

label

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

@en

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

@nl

prefLabel

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

@en

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

@nl

P1433

Q51718897-F3CC5367-8B73-4972-A935-9C7FAECDFC2D

P1476

Q51718897-7F2B07CA-2379-483E-8075-B49706B3EDEF

P2093

Q51718897-389685BD-7608-4AD3-B692-4E5B2F82703B

Q51718897-407C8E47-5E4D-4314-8C2F-DDD544017CEF

Q51718897-469FEE3E-B6AC-40A2-9432-450BDC489CBC

Q51718897-9267D8A8-D638-4AAE-8319-0BABB81E0D9A

Q51718897-95E4A3E1-A385-4BE3-B25F-684707285E65

Q51718897-97A8BD62-F58B-4737-9636-5613FEC66852

P2888

Q51718897-E3B4A8ED-4E01-4AB3-BB85-73C741FC6AC4

P304

Q51718897-0E907D8B-5090-40E6-9FDB-65BFD5DDD5E5

P31

Q51718897-9324DD75-5E72-4E2C-8FD6-BADEF3F136EF

P356

Q51718897-719FADCD-E07E-46FA-90F4-4B2E16A48724

P433

Q51718897-E14503CE-6D90-4A94-8F99-A551B395DAD9

P478

Q51718897-DAD38F82-C879-4064-8378-91E7B2EBD36D

P577

Q51718897-44931D0B-11EC-476C-BBF7-1F0C3560ADEE

P5875

Q51718897-BFD6833C-5BA5-4186-AB27-1897EF99169C

P698

Q51718897-EE86C5EC-500B-435E-97C4-7E6815FD9851

P921

Q51718897-991BB119-EC4C-4D6B-942E-19E0389BEB8E

Q51718897-C820C85B-3218-4998-9705-2B6ACB80B50A

P356

S00280-007-0664-8

P1433

Cancer Chemotherapy and Pharmacology

P1476

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

@en

P2093

Bert Lum

http://www.w3.org/2001/XMLSchema#string

Jacques Gaudreault

http://www.w3.org/2001/XMLSchema#string

Jian-Feng Lu

http://www.w3.org/2001/XMLSchema#string

Rene Bruno

http://www.w3.org/2001/XMLSchema#string

Steve Eppler

http://www.w3.org/2001/XMLSchema#string

William Novotny

http://www.w3.org/2001/XMLSchema#string

P2888

s00280-007-0664-8

P304

779-786

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-007-0664-8

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5646624

http://www.w3.org/2001/XMLSchema#string

P698

18205003

http://www.w3.org/2001/XMLSchema#string

P921